Human variability in xenobiotic metabolism and pathway-related uncertainty factors for chemical risk assessment: a review.

This review provides an account of recent developments arising from a database that defined human variability in phase I metabolism (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4, hydrolysis, alcohol dehydrogenase), phase II metabolism (N-acetyltransferases, glucuronidation, glycine conjugation, sulphation) and renal excretion. This database was used to derive pathway-related uncertainty factors for chemical risk assessment that allow for human variability in toxicokinetics. Probe substrates for each pathway of elimination were selected on the basis that oral absorption was >95% and that the metabolic route was the primary route of elimination of the compound (60-100% of a dose). Intravenous data were used for compounds for which absorption was variable. Human variability in kinetics was quantified for each compound from published pharmacokinetic studies (after oral and intravenous dosing) in healthy adults and other subgroups of the population using parameters relating to chronic exposure (metabolic and total clearances, area under the plasma concentration-time curve (AUC)) and acute exposure (Cmax) (data not presented here). The pathway-related uncertainty factors were calculated to cover 95%, 97.5% and 99% of the population of healthy adults and of each subgroup. Pathway-related uncertainty factors allow metabolism data to be incorporated into the derivation of health-based guidance values. They constitute an intermediate approach between the general kinetic default factors (3.16) and a chemical-specific adjustment factor. Applications of pathway-related uncertainty factors for chemical risk assessment and future refinements of the approach are discussed. A knowledge-based framework to predict human variability in kinetics for xenobiotics showing a threshold dose below which toxic effects are not observed, is proposed to move away from default assumptions.

[1]  Wolfgang Rohde,et al.  Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers , 2002, Clinical pharmacology and therapeutics.

[2]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.

[3]  R. Rawbone,et al.  Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes. , 2000, Toxicology letters.

[4]  A G Renwick,et al.  An analysis of the risk of exceeding the acceptable or tolerable daily intake. , 1993, Regulatory toxicology and pharmacology : RTP.

[5]  J. Blumer,et al.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). , 1988, Clinical pharmacokinetics.

[6]  A G Renwick,et al.  Toxicokinetics in infants and children in relation to the ADI and TDI. , 1998, Food additives and contaminants.

[7]  Harvey J Clewell,et al.  An approach for the quantitative consideration of genetic polymorphism data in chemical risk assessment: examples with warfarin and parathion. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  K Walton,et al.  Human variability for metabolic pathways with limited data (CYP2A6, CYP2C9, CYP2E1, ADH, esterases, glycine and sulphate conjugation). , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  A G Renwick,et al.  Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.

[10]  T. Turmen,et al.  Pharmacokinetics of diuretics and methylxanthines in the neonate , 1980, European Journal of Clinical Pharmacology.

[11]  T. Cresteil,et al.  Delayed ontogenesis of CYP1A2 in the human liver. , 1998, European journal of biochemistry.

[12]  B D Kahan,et al.  Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: Racial differences in bioavailability , 1992, Clinical pharmacology and therapeutics.

[13]  G. Kearns,et al.  Cytochrome P450 3A , 1999, Clinical pharmacokinetics.

[14]  M L Dourson,et al.  Evolution of science-based uncertainty factors in noncancer risk assessment. , 1996, Regulatory toxicology and pharmacology : RTP.

[15]  J. Steven Leeder,et al.  Glucuronidation in Humans , 1999, Clinical pharmacokinetics.

[16]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[17]  G. Elizondo,et al.  CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity , 2000, Clinical pharmacology and therapeutics.

[18]  K Walton,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[19]  L. Costa,et al.  Polymorphisms of Paraoxonase (PON1) and Their Significance in Clinical Toxicology of Organophosphates , 2003, Journal of toxicology. Clinical toxicology.

[20]  T. Cresteil.  Onset of xenobiotic metabolism in children: toxicological implications. , 1998, Food additives and contaminants.

[21]  D. Kupfer,et al.  Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[22]  M. Debiec‐Rychter,et al.  Metabolism of aromatic amines: relationships of N-acetylation, O-acetylation, N,O-acetyltransfer and deacetylation in human liver and urinary bladder. , 1989, Carcinogenesis.

[23]  M. Lebel,et al.  Benzyl alcohol metabolism and elimination in neonates. , 1988, Developmental pharmacology and therapeutics.

[24]  P. Gow,et al.  Neonatal hepatic drug elimination. , 2001, Pharmacology & toxicology.

[25]  E. Hodgson,et al.  In vitro metabolism of carbaryl by human cytochrome P450 and its inhibition by chlorpyrifos. , 2002, Chemico-biological interactions.

[26]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[27]  K Walton,et al.  Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  K Walton,et al.  Default Factors for Interspecies Differences in the Major Routes of Xenobiotic Elimination , 2001 .

[29]  A. Renwick,et al.  Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.

[30]  L. Bertilsson,et al.  Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. , 1999, Pharmacogenetics.

[31]  R Truhaut,et al.  The concept of the acceptable daily intake: an historical review. , 1991, Food additives and contaminants.

[32]  Karthik Venkatakrishnan,et al.  Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models , 2001, Journal of clinical pharmacology.

[33]  D Hattis,et al.  Human variability in susceptibility to toxic chemicals--a preliminary analysis of pharmacokinetic data from normal volunteers. , 1987, Risk analysis : an official publication of the Society for Risk Analysis.

[34]  J. Dorne,et al.  Human variability in glucuronidation in relation to uncertainty factors for risk assessment. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[35]  H. Klenk,et al.  Identification and functional characterization of eight CYP3A4 protein variants. , 2001, Pharmacogenetics.

[36]  C. Hunt,et al.  Effect of age and gender on the activity of human hepatic CYP3A. , 1992, Biochemical pharmacology.

[37]  Kenny S. Crump,et al.  Calculation of Benchmark Doses from Continuous Data , 1995 .

[38]  J. Dorne,et al.  Human variability in the renal elimination of foreign compounds and renal excretion-related uncertainty factors for risk assessment. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[39]  David E. Burmaster,et al.  Human Interindividual Variability in Parameters Related to Health Risks , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[40]  K. Mcculloch,et al.  Alterations in theophylline metabolism during the first year of life , 1993, Clinical pharmacology and therapeutics.

[41]  J. Johnson,et al.  Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. , 2000, International journal of clinical pharmacology and therapeutics.

[42]  J. Dorne,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[43]  K Walton,et al.  Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[44]  D Hattis,et al.  Risk evaluation: criteria arising from legal traditions and experience with quantitative risk assessment in the United States. , 1996, Environmental toxicology and pharmacology.

[45]  G. Koren,et al.  Intravenous and Oral Propafenone for Treatment of Tachycardia in Infants and Children: Pharmacokinetics and Clinical Response , 1998, Journal of clinical pharmacology.

[46]  J. Dorne,et al.  Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[47]  Edward V. Sargent,et al.  Use of toxicokinetic and toxicodynamic data to reduce uncertainties when setting occupational exposure limits for pharmaceuticals , 1997 .

[48]  U. Meyer,et al.  Polymorphism of human acetyltransferases. , 1994, Environmental health perspectives.

[49]  O. G. Fitzhugh,et al.  100-Fold margin of safety , 1954 .

[50]  Bruce D. Naumann,et al.  Scientific basis for uncertainty factors used to establish occupational exposure limits for pharmaceutical active ingredients , 1995 .

[51]  Edward V. Sargent,et al.  Establishing Data-Derived Adjustment Factors from Published Pharmaceutical Clinical Trial Data , 1999 .

[52]  K Walton,et al.  An analysis of the need for an additional uncertainty factor for infants and children. , 2000, Regulatory toxicology and pharmacology : RTP.

[53]  W. Slob,et al.  A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework , 1998 .

[54]  Y. Sugiyama,et al.  Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[56]  M L Dourson,et al.  Regulatory history and experimental support of uncertainty (safety) factors. , 1983, Regulatory toxicology and pharmacology : RTP.

[57]  P. Wedlund.  The CYP2C19 Enzyme Polymorphism , 2000, Pharmacology.

[58]  J. Blumer,et al.  Principles of Drug Biodisposition in the Neonate , 2012 .

[59]  J. Casida,et al.  Imidacloprid insecticide metabolism: human cytochrome P450 isozymes differ in selectivity for imidazolidine oxidation versus nitroimine reduction. , 2002, Toxicology letters.

[60]  J. Goldstein,et al.  Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[61]  W. Slob,et al.  Mathematical modelling and quantitative methods. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[62]  A. Mclean,et al.  The Aging Liver , 1998, Clinical pharmacokinetics.

[63]  J. Goldstein,et al.  Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. , 2002, Pharmacogenetics.

[64]  W Slob,et al.  Assessment factors for human health risk assessment: a discussion paper. , 1999, Critical reviews in toxicology.

[65]  K Walton,et al.  Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[66]  Michael Dourson,et al.  A Probabilistic Framework for the Reference Dose (Probabilistic RfD) , 1998 .

[67]  M. Plissonnier,et al.  Maturation of Caffeine N-Demethylation in Infancy: A Study Using the 13CO2 Breath Test , 1988, Pediatric Research.

[68]  E. Testai,et al.  CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. , 2003, Toxicology and applied pharmacology.

[69]  J. Dorne,et al.  Polymorphic CYP2C19 and N-acetylation: human variability in kinetics and pathway-related uncertainty factors. , 2003, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[70]  Wout Slob,et al.  Thresholds in Toxicology and Risk Assessment , 1999 .

[71]  C. Loi,et al.  Hepatic Drug Metabolism and Aging , 1990, Clinical pharmacokinetics.

[72]  A. Renwick.  Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.

[73]  B. Lin,et al.  Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. , 1993, American journal of human genetics.

[74]  C. Cazeneuve,et al.  Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. , 1994, British journal of clinical pharmacology.

[75]  Edward V. Sargent,et al.  Case Studies of Categorical Data-Derived Adjustment Factors , 2001 .

[76]  Dale Hattis,et al.  Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants. , 2004, Toxicology and applied pharmacology.

[77]  K S Crump,et al.  A new method for determining allowable daily intakes. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.